The FDA’s Oncologic Drugs Advisory Committee (ODAC) convened today to consider Biologics License Applications (BLAs) for 2 biosimilar products: ABP 215, Amgen’s bevacizumab biosimilar candidate (referenced on Avastin), and MYL-1401O, Mylan and Biocon’s biosimilar trastuzumab candidate (referenced on Herceptin).
The FDA’s Oncologic Drugs Advisory Committee (ODAC) convened today to consider Biologics License Applications (BLAs) for 2 biosimilar products: ABP 215, Amgen’s bevacizumab biosimilar candidate (referenced on Avastin), and MYL-1401O, Mylan and Biocon’s biosimilar trastuzumab candidate (referenced on Herceptin).
During the consideration of ABP 215, FDA reviewers stated that they found no clinically meaningful differences between ABP 215 and the reference bevacizumab, adding to the totality of the evidence to support a demonstration of biosimilarity. The reviewers added that, in their view, an extrapolation of biosimilarity for all indications for which Amgen seeks approval is justified.
In a vote on whether the totality of the evidence supported licensure of ABP 215 as a biosimilar to Avastin for all of the indications sought by Amgen, all 17 committee members voted yes, based on what committee members called “clean and clear” evidence and “tight confidence intervals.”
However, during the discussion of their vote, some members of the committee raised lingering concerns: the group noted that pharmacovigilance for ABP 215 will be important moving forward. Some members of the committee also raised concerns about the homogeneity of the patient population studied in the clinical trials, noting that the patients were overwhelmingly white and exclusively male, and called for including a more diverse patients population.
In the second half of ODAC’s proceedings, the committee considered MYL-1401O. Presenting for the applicant, Hope Rugo, MD, clinical professor and director of the Breast Oncology Clinical Trials Program at the University of California at San Francisco, gave a clinical perspective in support of the drug. Rugo stated that trastuzumab is responsible for “curing women who otherwise would not be cured of breast cancer,” and that, if the biosimilar is approved, newly diagnosed patients with HER2-positive metastatic breast cancer will have the option to start their treatment with a lower-cost biosimilar. Other representatives for Mylan highlighted the fact that the patient population studied in its clinical trials was “a broad and sensitive treatment population.”
FDA reviewers, in summarizing their analysis of data provided by Mylan and Biocon, stated that the totality of the evidence supports demonstration of similarity, and no clinically meaningful differences were detected between the 2 products. Extrapolations to all indications sought by the biosimilar applicant is, the reviewers indicated, supported.
As the panel discussed the drug, the sponsor was called upon to address panelists’ questions concerning the following:
As in the public comment portion of the proceedings on ABP 215, patient advocates broadly supported the approval of biosimilar trastuzumab to improve patient access. However, those speaking in support of MYL-1401O included such experts as Edward Li, PharmD, MPH, BCOP, professor of Pharmacy Practice for the University of New England College of Pharmacy, who urged the FDA to approve the biosimilar product in order to help control costs.
On the voting question of whether the totality of the evidence supported licensure of the product as a biosimilar product to Herceptin for all indications, all 16 attending committee members voted yes.
None of the committee members, either in the discussion of the drug or in the post-voting comments, raised questions or concerns related to Mylan and Biocon’s recent regulatory troubles abroad. On July 5, the French regulatory body, the National Agency for Medicines and Health Products Safety (ANSM) found that Biocon’s manufacturing facility in Bangalore had failed to follow good manufacturing practices for 3 biosimilar products, including MYL-1401O. The ANSM will re-inspect the facility, but the product’s European market entry could be delayed indefinitely until the European Medicines Agency is confident that the company has taken action to correct the deficiencies identified in the inspection.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Eye on Pharma: Interchangeability Labels and Expanded Biosimilar Partnerships
May 29th 2025The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple sclerosis, while 2 other companies expand their biosimilar partnership to include more products.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21st 2025Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.